Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
January 14th, 2011
An efficient protocol for the ex vivo expansion of tumor-reactive T cells from tumor-draining lymph nodes or other secondary lymphoid tissues of tumor-bearing hosts is described. This protocol selectively expands tumor-specific T cells for use in adoptive immunotherapy of breast cancer.
The goals of this experiment are to induce activation of T-cell by Brios statin one ion mycin, as well as differentiation of T-cells by gamma chain cytokines begin with the isolation of tumor sensitized T-cells from spleen and lymph nodes. Then activate with brios statin one and ion mycin two intracellular signal mimetics that increase protein kinase C activity and intracellular calcium respectively. Culture in the presence of IL seven IL 15, and IL two for the differentiation and expansion of tumor reactive T cells.
The powerful combination of results from the interferon gamma EISA and the fact cytotoxicity assay can shed light on tumor reactivity of the expanded T cells and offer potential insights to adoptive immunotherapy. This method of exvivo expansion of tumor reactive T cells can help answer key questions in tumor immunology questions such as what is the role of common gamma imaging cytokines in the differentiation of tumor reactive T cells. And what is the role of each T-cell phenotype such as effector cells, effector memory cells, and central memory cells in generating long-term memory response against cancer.
The insulation of lymph nodes and spleen and the septic handling of the lymphocytes are difficult procedures to implement but can be learned rapidly. By observation. The FVBN 2 0 2 transgenic female mice express an inactivated rat new transgene under the regulation of MMTV promoter and as a result, developed spontaneous mammary carcinoma between four and 10 months of age.
In this protocol, these spontaneous tumor bearing mice are used as donors of tumor reactive T cells. To begin isolate the tumor draining lymph nodes and spleens from tumor bearing FVBN 2 0 2 transgenic mice. Now prepare a single cell suspension in ice cold RPMI 1640 supplemented with 10%FB sce A culture at 10 to the six cells per milliliter in complete medium containing 15%FBS with one micromolar cin five nano molar brios statin one and 80 units per milliliter.
IL two for 16 hours with our PMI medium equilibrated at 37 degrees Celsius, wash the cells three times, then culture at 10 to the six cells per milliliter in complete medium with 10 nanograms per milliliter, each of IL seven and IL 15 for 24 hours. In order to further activate the cells pulse with an addition of 40 units per milliliter IL two for 24 hours. Now split the cells and culture them with 10 nanograms per milliliter, each of IL seven and IL 15 for four more days if necessary, change the medium and split the cells every two days.
Harvest the expanded primary T cells by centrifugation, enumerate the cells by light microscopy and calculate the fold expansion of T cells. Now prepare the cells for flow cytometry to determine the proportion of CD eight positive and CD four positive T cells. First block non-specific binding of antibodies to FC receptors by incubating the cells with anti CD 16, CD 32 antibody for 20 minutes on ice.
Then wash the cells twice with two milliliters of ice cold PBS supplemented with 1%sodium azide stain the cells by incubating with Fitz CD four and PE CD eight antibodies for 20 minutes on ice. Wash twice with two milliliters of ice cold PBS supplemented with 1%FBS and 0.1%sodium azide. Finally, fix the cells with 1%paraform aldehyde and analyze the samples on a Beckman Coulter FC 500 using summit version 4.3 software in six well culture plates, pipette T cells with mammary tumor cells in a 10 to one effector to target ratio and three milliliters per well.
Complete medium containing 20 units per milliliter of IL two incubate at 37 degrees Celsius and 5%carbon dioxide for 48 hours. Perform three color antibody staining for new, followed by PE anti-US IgG and Xin five fite and propidium iodide according to the manufacturer's protocol gate facts on new positive tumor cells and analyze viability of the tumor cells with an Xin five pi. An activation of T cells with BI for 16 hours results in killing of naive T cells that are not sensitized with the tumor in vivo.
After the bi selectivity of tumor reactive T cells, they expand up to 2.8 fold within a six day culture with the gamma chain cytokines, both CD eight positive and CD four positive T cells are equally expanded with the gamma chain cytokines. After a six day ex vivo culture, the ex vivo expanded T cells show high responsiveness against the tumors that donor mice were sensitized to as evaluated by the production of interferon gamma. In the presence of new positive mouse mammary carcinoma or MMC tumor cells, the ex vivo expanded T cells can induce apoptosis in the new positive MMC tumor cells, such that viability of the tumor cells drops from 92%to 61%within 48 hours.
While attempting this procedure, you should remember to work under aseptic conditions. After watching this video, you should have a good understanding of how to select and expand tumor active T-cells for adaptive T-cell therapy of cancers.
View the full transcript and gain access to thousands of scientific videos
Overview
This article presents an efficient protocol for the ex vivo expansion of tumor-reactive T cells from tumor-draining lymph nodes or other secondary lymphoid tissues. The method aims to selectively expand tumor-specific T cells for potential use in adoptive immunotherapy of breast cancer.
Key Study Components
Area of Science
- Immunology
- Oncology
- Cell Biology
Background
- Tumor-reactive T cells play a crucial role in cancer immunotherapy.
- Understanding T cell differentiation is essential for effective treatment strategies.
- Adoptive immunotherapy involves the transfer of T cells to enhance anti-tumor responses.
- Common gamma chain cytokines are important for T cell activation and differentiation.
Purpose of Study
- To develop a protocol for expanding tumor-reactive T cells.
- To investigate the role of cytokines in T cell differentiation.
- To explore the phenotypes of T cells involved in long-term memory responses against cancer.
Methods Used
- Isolation of tumor-sensitized T cells from spleen and lymph nodes.
- Activation of T cells using Brios statin and ionomycin.
- Culturing T cells with IL-7, IL-15, and IL-2 for differentiation and expansion.
- Utilization of interferon gamma ELISA and cytotoxicity assays to assess tumor reactivity.
Main Results
- The protocol successfully expands tumor-reactive T cells.
- Activation and differentiation of T cells were achieved using specific cytokines.
- Insights into T cell phenotypes were gained, contributing to understanding memory responses.
- The findings support the potential of this method in adoptive immunotherapy.
Conclusions
- This ex vivo expansion method can enhance tumor immunology research.
- Understanding T cell differentiation is vital for improving cancer therapies.
- The study provides a foundation for future investigations into T cell roles in cancer.
Frequently Asked Questions
Executive Industry Relevance
This protocol enables selective expansion of tumor-reactive T cells without requiring tumor antigens ex vivo, addressing a key bottleneck in adoptive T-cell therapy manufacturing. By leveraging bryostatin-1/ionomycin activation followed by common gamma chain cytokine culture, the method achieves antigen-independent enrichment of tumor-specific T cells, improving predictive confidence in preclinical immunotherapy models. The approach supports mechanistic de-risking of T-cell therapies by isolating variables that drive tumor specificity and expansion, informing go/no-go decisions in early discovery.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of tumor-specific T-cell reactivity by selectively expanding antigen-experienced lymphocytes while depleting naive bystander cells.
- Operational Value: Provides a reproducible system to validate tumor-associated antigen targets using interferon-gamma ELISA and cytotoxicity assays as functional readouts.
- Predictive Value: Supports phenotypic profiling of CD4+/CD8+ T-cell subsets to assess memory potential and long-term antitumor efficacy.
Screening & Assay Development
- Assay Readiness: Generates expanded T-cell populations suitable for high-throughput screening of immunomodulators or checkpoint inhibitors using standardized effector-to-target ratios.
- Quantitative Outputs: Enables measurement of tumor-specific interferon-gamma secretion and tumor-cell apoptosis as dependent variables for assay validation.
- Reproducibility: Defined cytokine dosing (IL-7/IL-15 pulse followed by IL-2) and culture timing ensure consistent fold-expansion (~2.8x) across experiments.
Translational & Preclinical Research
- Disease Relevance: Uses the FVB/N202 HER-2/neu transgenic mouse model to generate tumor-reactive T cells spontaneous mammary carcinoma, enhancing translational fidelity.
- Preclinical Continuity: Expanded T cells demonstrate tumor-specific apoptosis induction in vivo-relevant assays, supporting risk-adjusted advancement decisions.
- Biomarker Alignment: Links T-cell phenotype (effector/memory ratios) to functional outcomes, enabling mechanistic de-risking of therapeutic candidates.
Pipeline & Workflow Integration
The method fits within the discovery-to-preclinical continuum by providing a standardized approach to generate tumor-reactive T cells for immunotherapy screening, positioned after target identification and before lead optimization in immuno-oncology pipelines.
- Discovery Biology: Supports hypothesis testing of tumor antigen specificity through selective T-cell expansion without exogenous peptide pulsing.
- Screening: Delivers assay-ready T-cell products with defined reactivity thresholds (e.g., >30% tumor-cell apoptosis at 48 hours) for compound evaluation.
- Analytics: Enables quantitative comparison of T-cell functionality via interferon-gamma ELISA and live/dead tumor-cell assays, informing structure-activity relationships.
- Translational Research: Connects ex vivo expansion metrics to antitumor efficacy in syngeneic models, supporting IND-enabling studies.
- Enterprise Reuse: Establishes a cytokine-based T-cell expansion platform adaptable to multiple tumor models and therapeutic modalities.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in T-cell therapy by isolating tumor-reactive subsets through activation-induced cell death of bystander cells.
- Operational Value: Standardizes T-cell production using defined cytokine concentrations and timed culture steps, improving batch consistency.
- Strategic Value: Increases confidence in go/no-go decisions by providing quantitative tumor-reactivity data prior to in vivo validation.
- Portfolio Impact: Enables risk-adjusted prioritization of immunotherapy candidates based on expanded T-cell specificity and expansion kinetics.
Implementation Considerations
- Requires expertise in primary lymphocyte isolation from lymphoid tissues and aseptic cell culture techniques.
- Dependent on access to bryostatin-1, ionomycin, and recombinant gamma chain cytokines (IL-2, IL-7, IL-15) with precise dosing controls.
- Necessitates standardized workflows for interferon-gamma ELISA and cytotoxicity assay execution to ensure cross-team comparability.
- Requires adaptation of cell-splitting schedules and medium changes when scaling beyond 10^6 cells/mL culture density.
- Limited by the need for tumor-bearing donor models to isolate tumor-sensitized T cells, restricting applicability to syngeneic or humanized systems.
Biopharma FAQs
Chapters in this video
0:05
Title
0:55
Introduction
1:48
Mouse Model of Breast Cancer
2:14
Isolation of Lymphocytes
3:44
Determine Fold Expansion of T Cells by Cell Counts and Flow Cytometry Analysis
4:58
Determine Tumor-Specificity of the ex vivo Expanded T Cells
5:47
Selective Expansion of Tumor-Reactive T Cells with Effector Anti-Tumor Function
6:53
Conclusion
